share_log

CFO & Treasurer Of Merit Medical Systems Sold 46% Of Their Shares

CFO & Treasurer Of Merit Medical Systems Sold 46% Of Their Shares

Merit Medical Systems的首席财务官兼财务主管出售了46%的股份
Simply Wall St ·  03/15 06:35

Anyone interested in Merit Medical Systems, Inc. (NASDAQ:MMSI) should probably be aware that the CFO & Treasurer, Raul Parra, recently divested US$479k worth of shares in the company, at an average price of US$73.95 each. That sale was 46% of their holding, so it does make us raise an eyebrow.

任何对Merit Medical Systems, Inc.(纳斯达克股票代码:MMSI)感兴趣的人都应该知道,首席财务官兼财务主管劳尔·帕拉最近剥离了该公司价值47.9万美元的股份,平均每股价格为73.95美元。那次出售占他们持股量的46%,因此确实让我们大吃一惊。

Merit Medical Systems Insider Transactions Over The Last Year

Merit Medical Systems 去年内幕交易

Notably, that recent sale by Raul Parra is the biggest insider sale of Merit Medical Systems shares that we've seen in the last year. So we know that an insider sold shares at around the present share price of US$71.93. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern.

值得注意的是,劳尔·帕拉最近的出售是我们去年对Merit Medical Systems股票的最大一次内幕出售。因此,我们知道一位内部人士以目前的71.93美元左右的股价出售了股票。我们通常不喜欢看到内幕销售,但是销售价格越低,我们就越担心。鉴于此次出售是以当前价格进行的,这使我们有点谨慎,但并不是一个主要问题。

Insiders in Merit Medical Systems didn't buy any shares in the last year. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

去年,Merit Medical Systems的内部人士没有购买任何股票。下图显示了去年的内幕交易(公司和个人)。通过点击下面的图表,你可以看到每笔内幕交易的确切细节!

insider-trading-volume
NasdaqGS:MMSI Insider Trading Volume March 15th 2024
纳斯达克GS: MMSI 内幕交易量 2024 年 3 月 15 日

I will like Merit Medical Systems better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

如果我看到一些重大的内幕收购,我会更喜欢Merit Medical Systems的。在我们等待的同时,请查看这份免费清单,列出了最近有大量内幕收购的成长型公司。

Does Merit Medical Systems Boast High Insider Ownership?

Merit Medical Systems 是否拥有很高的内部所有权?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. Insiders own 2.3% of Merit Medical Systems shares, worth about US$99m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

查看公司的内部持股总量可以帮助你了解他们是否与普通股股东保持一致。我们通常希望看到相当高的内部所有权水平。内部人士拥有Merit Medical Systems2.3%的股份,价值约9900万美元。这种内部所有权水平不错,但还没有特别突出。这无疑表明了一定程度的一致性。

So What Does This Data Suggest About Merit Medical Systems Insiders?

那么,这些数据对Merit Medical Systems内部人士有什么启示呢?

Insiders haven't bought Merit Medical Systems stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. On the plus side, Merit Medical Systems makes money, and is growing profits. While insiders do own shares, they don't own a heap, and they have been selling. We'd practice some caution before buying! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Every company has risks, and we've spotted 1 warning sign for Merit Medical Systems you should know about.

内部人士在过去三个月中没有购买Merit Medical Systems的股票,但出现了一些抛售。展望过去的十二个月,我们的数据并未显示任何内幕买盘。从好的方面来看,Merit Medical Systems赚了钱,而且利润也在增长。尽管内部人士确实拥有股票,但他们并不拥有大量股票,他们一直在抛售。购买前我们会谨慎行事!因此,这些内幕交易可以帮助我们建立有关股票的论点,但也值得了解这家公司面临的风险。每家公司都有风险,我们发现了一个你应该知道的Merit Medical Systems警告信号。

But note: Merit Medical Systems may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

但请注意:Merit Medical Systems可能不是最好的买入股票。因此,来看看这份投资回报率高、债务低的有趣公司的免费清单。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发